Flag of the European Union EU Clinical Trials Register Help

Clinical trials for PRP

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    196 result(s) found for: PRP. Displaying page 7 of 10.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    EudraCT Number: 2017-004181-10 Sponsor Protocol Number: A3L35 Start Date*: 2017-12-04
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Sanofi Pasteur’s DTaP IPV HB PRP~T Combined Vaccine Given as a Three-Dose Primary Series at 2, 3, 4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Month...
    Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus type 1, 2 and 3, prevention against invasive infections caused by Haemophilus in...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    20.0 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    20.0 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    20.0 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001716-38 Sponsor Protocol Number: 1404-BIO-019-MF Start Date*: 2017-04-26
    Sponsor Name:IVI BILBAO
    Full Title: Influence instillation plasma rich in growth factors in endometrial cavity
    Medical condition: Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type. Less than 5 mm Endometrio despite 10 days with standard doses of estrogen therapy (6...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006445-13 Sponsor Protocol Number: PROM 2006/0634 Start Date*: 2007-05-10
    Sponsor Name:Centre hospitalier Régional et Universitaire
    Full Title: Programme de réhabilitation précoce dans les Néphrectomie totales pour cancer du rein
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002578-31 Sponsor Protocol Number: X05-AR21-302 Start Date*: 2005-09-14
    Sponsor Name:Sanofi Pasteur MSD S.N.C.
    Full Title: A controlled, double-blind and randomized study, to compare the immunogenicity and safety of HEXAVAC manufactured by an upgraded process to HEXAVAC manufactured by the current process when given to...
    Medical condition: The vaccine is indicated for primary and booster vaccination of children against six infectious diseases: diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis caused by 3 types of poliovirus ...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006460-32 Sponsor Protocol Number: 109664,109666,109668 Start Date*: 2007-03-26
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, open, multicenter, multicountry study to assess the long-term antibody persistence of a booster dose of GlaxoSmithKline (GSK) Biologicals’ Haemophilus influenzae type b – meningococcal ...
    Medical condition: Persistence of antibodies after a 3-dose primary vaccination (in infancy) with or without a booster vaccination (in the second year of life) against Haemophilus influenzae type b disease and menin...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005404-29 Sponsor Protocol Number: E2I60 Start Date*: 2015-12-04
    Sponsor Name:SANOFI PASTEUR SA
    Full Title: Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China
    Medical condition: Healthy volunteers: active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by Haemophilus influenzae type b (such as meningitis, septicaemia, cellu...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10036897 Prophylactic vaccination LLT
    18.1 10042613 - Surgical and medical procedures 10043413 Therapeutic procedures and supportive care NEC HLGT
    18.1 10042613 - Surgical and medical procedures 10021430 Immunisation PT
    18.1 10042613 - Surgical and medical procedures 10021431 Immunisations HLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-000898-30 Sponsor Protocol Number: A5I19 Start Date*: 2006-07-05
    Sponsor Name:Sanofi Pasteur Incorporated
    Full Title: Safety and Immunogenicity of Booster Vaccination with PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conj...
    Medical condition: PEDIACEL is a fully liquid combination vaccine indicated for infants and children for the prevention of five infectious diseases (diphtheria, tetanus, pertussis, poliomyelitis and infections caused...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001539-19 Sponsor Protocol Number: 104298 Start Date*: 2015-05-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIb randomized, double-blind, controlled study of the safety, immunogenicity and proof-of-concept of RTS,S/AS02D, a candidate malaria vaccine, when incorporated into an Expanded Program on ...
    Medical condition: Healthy volunteers (Primary immunization against Plasmodium falciparum malaria).
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004120-21 Sponsor Protocol Number: COX1985 Start Date*: 2016-01-22
    Sponsor Name:FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD
    Full Title: CLINICAL TRIAL RANDOMIZED, DOUBLE-BLIND CONTROLLED, PHASE III, TO EVALUATE THE USE OF PLATELET RICH PLASMA IN FRONT HYALURONIC ACID IN COXARTHROSIS.
    Medical condition: coxarthrosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10058417 Hyaluronic acid PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003427-10 Sponsor Protocol Number: 111157 Start Date*: 2015-05-04
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) administered to I...
    Medical condition: Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, polio and Hib diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023865-22 Sponsor Protocol Number: P13UK Start Date*: 2011-01-05
    Sponsor Name:Health Protection Agency
    Full Title: A prospective study to evaluate the immune response of UK infants receiving the 13-valent pneumococcal conjugate vaccine as part of their routine primary immunisation schedule at 2 and 4 months (co...
    Medical condition: Prevenar13 was introduced into the national childhood immunisation programme to prevent serious bacterial infections caused by the germ Streptococcus pneumonia, including meningitis, septicaemia an...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004095-10 Sponsor Protocol Number: V419-005 Start Date*: 2012-02-20
    Sponsor Name:Sanofi Pasteur Limited
    Full Title: A Phase III Randomized, Open-Label, Active-Comparator Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Infants When Given at 2, 4, and 6 Months Conco...
    Medical condition: PR5I is developed to provide active immunization against diphtheria, tetanus, pertussis, poliomyelitis (caused by poliovirus Types 1, 2 and 3), invasive disease caused by Haemophilus influenza type...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054130 Hepatitis B immunisation PT
    14.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    14.1 10042613 - Surgical and medical procedures 10053386 Poliomyelitis vaccine LLT
    14.1 10042613 - Surgical and medical procedures 10069543 Hemophilus influenzae type b immunization LLT
    14.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    14.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    14.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002413-11 Sponsor Protocol Number: PRI01C Start Date*: 2012-02-07
    Sponsor Name:Sanofi Pasteur MSD S.N.C
    Full Title: A phase III open-label randomised study, to evaluate the immunogenicity and safety of the concomitant administration of V419 (PR5I) given at 2, 3 and 4 months of age with two types of meningococcal...
    Medical condition: PR5I is developed to provide active immunization against diphtheria, tetanus, pertussis, poliomyelitis (caused by poliovirus Types 1, 2 and 3), invasive disease caused by Haemophilus influenza ty...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054183 Tetanus immunization LLT
    14.1 10022891 - Investigations 10019743 Hepatitis B virus (HBV) LLT
    14.1 10042613 - Surgical and medical procedures 10054181 Hepatitis B immunization LLT
    14.1 10042613 - Surgical and medical procedures 10069593 Pertussis immunization LLT
    14.1 10042613 - Surgical and medical procedures 10054180 Diphtheria immunization LLT
    14.1 10042613 - Surgical and medical procedures 10053386 Poliomyelitis vaccine LLT
    14.1 10042613 - Surgical and medical procedures 10069543 Hemophilus influenzae type b immunization LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001120-30 Sponsor Protocol Number: 201334 Start Date*: 2016-05-29
    Sponsor Name:GlaxoSmithKline S.A.
    Full Title: A phase IV, open-label, non-randomised, multi-centre study to assess the immunogenicity and safety of a booster dose of Infanrix hexa? in healthy infants born to mothers vaccinated with Boostrix? d...
    Medical condition: Infanrix Hexa is indicated for the prevention of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b (Hib).
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) Outside EU/EEA FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021491-28 Sponsor Protocol Number: V419-008 Start Date*: 2012-01-26
    Sponsor Name:Sanofi Pasteur MSD S.N.C.
    Full Title: A phase III randomized, double-blind, active-comparator controlled clinical trial to study the safety, tolerability, and immunogenicity of V419 in healthy infants when given at 2, 4, and 11 to 12 m...
    Medical condition: PR5I is developed to provide active immunization against diphtheria, tetanus, pertussis, poliomyelitis (caused by poliovirus Types 1, 2 and 3), invasive disease caused by Haemophilus influenza type...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004848 10019743 Hepatitis B virus (HBV) LLT
    16.0 100000004865 10069543 Hemophilus influenzae type b immunization LLT
    16.0 100000004865 10069593 Pertussis immunization LLT
    16.0 100000004865 10054181 Hepatitis B immunization LLT
    16.0 100000004865 10053386 Poliomyelitis vaccine LLT
    16.0 100000004865 10054180 Diphtheria immunization LLT
    16.0 100000004865 10054183 Tetanus immunization LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001117-41 Sponsor Protocol Number: 201330 Start Date*: 2015-11-13
    Sponsor Name:GlaxoSmithKline S.A.
    Full Title: A phase IV, open-label, non-randomised, multi-centre study to assess the immunogenicity and safety of Infanrix hexa? administered as primary vaccination in healthy infants born to mothers given Boo...
    Medical condition: Healthy volunteers [Primary immunisation of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b (Hib)].
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10006025 Bordetella pertussis laryngotracheobronchitis LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) Outside EU/EEA FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004108-39 Sponsor Protocol Number: V419-006 Start Date*: 2012-02-20
    Sponsor Name:Sanofi Pasteur Limited
    Full Title: A Phase III Randomized, Partially Double-Blind, Active- Comparator-Controlled, Lot-to-Lot Consistency Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Healthy I...
    Medical condition: PR5I is developed to provide active immunization against diphtheria, tetanus, pertussis, poliomyelitis (caused by poliovirus Types 1, 2 and 3), invasive disease caused by Haemophilus influenza type...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054130 Hepatitis B immunisation PT
    14.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    14.1 10042613 - Surgical and medical procedures 10053386 Poliomyelitis vaccine LLT
    14.1 10042613 - Surgical and medical procedures 10069543 Hemophilus influenzae type b immunization LLT
    14.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    14.1 10021881 - Infections and infestations 10019731 Hepatitis B PT
    14.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001249-28 Sponsor Protocol Number: MU2017/001 Start Date*: 2019-05-21
    Sponsor Name:Mutua Universal MUGENAT
    Full Title: Phase III, Single-blinded, placebo-Controlled and randomized Clinical Trial with minimal intervention on the Treatment with Plasma Rich in Growth Factors (PRGF) of Work-site Acute Epicondylitis Res...
    Medical condition: Epicondylitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10014971 Epicondylitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000549-20 Sponsor Protocol Number: 106744 Start Date*: 2006-07-20
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in healthy children 7 to 9 year...
    Medical condition: Four dose vaccination course with GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine or with GSK Biologicals’ HBV vaccine, given as a three dose primary vaccination series in the first year of life, followe...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004581-34 Sponsor Protocol Number: FIHP201801 Start Date*: 2019-04-02
    Sponsor Name:Fundación Instituto Hispalense de Pediatría
    Full Title: An open-label Phase IV trial to evaluate the immunogenicity and safety of Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus infl...
    Medical condition: Vaccines, Bacterial and viral vaccines combined
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 13:27:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA